Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

被引：0
|
作者：
Carole Dembek
Leigh Ann White
Jayson Quach
Andrea Szkurhan
Nazia Rashid
M. R. Blasco
机构：
[1] Avalere Health,
[2] Biogen Idec,undefined
[3] Dymaxium,undefined
[4] Hospital Universitario Puerta de Hierro,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 362
页数：9
相关论文
共 50 条
  • [21] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [22] Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
    Goldberg, Lawrence D.
    Edwards, Natalie C.
    Fincher, Contessa
    Doan, Quan V.
    Al-Sabbagh, Ahmad
    Meletiche, Dennis M.
    JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (07): : 543 - 555
  • [23] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [24] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [25] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [26] The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
    Burton, Jodie M.
    Freedman, Mark S.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2018, 38 (02) : 210 - 216
  • [27] CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS.
    Zieiba, P.
    Pawlik, D.
    Wieczorek, J.
    Wojcik, R.
    Kaczor, M. P.
    VALUE IN HEALTH, 2020, 23 : S632 - S632
  • [28] Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review
    Eduardo Navarro, Cristian
    Ordonez-Callamand, Eliana
    Pablo Alzate, Juan
    FARMACIA HOSPITALARIA, 2020, 44 (02) : 68 - 76
  • [29] THE IMPACT OF NEUTRALIZING ANTIBODY TESTING ON THE COST-EFFECTIVENESS OF INJECTABLE DISEASE MODIFYING TREATMENTS FOR RELAPSING REMITTING MULTIPLE SCLEROSIS
    Andreykiv, M.
    Plich, A.
    Prufert, A.
    Heemstra, L.
    Van Engen, A.
    VALUE IN HEALTH, 2015, 18 (03) : A284 - A284
  • [30] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
    Nasrin Abulhasanbeigi Gallehzan
    Majid Khosravi
    Khosro Jamebozorgi
    Nazanin Mir
    Habib Jalilian
    Samira Soleimanpour
    Saeed Hoseini
    Aziz Rezapour
    Abbas Eshraghi
    Health Economics Review, 14
12345